(16 days)
Not Found
No
The device description and performance studies focus on the mechanical and fluid dynamics of an implanted port system, with no mention of AI or ML technologies.
Yes
The device is described as an implanted port system used for patient therapies requiring repeated access to the vascular system for infusion of medications, I.V. fluids, parenteral nutrition solutions, blood products, and withdrawal of blood samples. These activities are therapeutic in nature.
No
This device is an implanted port system used for infusion and withdrawal of fluids from the vascular system, not for diagnosing medical conditions.
No
The device description clearly details physical components like a port body, septum, catheter, and stem, indicating it is a hardware device for vascular access.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "patient therapies requiring repeated access to the vascular system" for infusion and withdrawal of substances. This is a direct interaction with the patient's body for therapeutic and diagnostic sampling purposes, not for testing samples in vitro (outside the body).
- Device Description: The description details a physical implantable device (port and catheter) designed to be placed within the body to provide vascular access. This is characteristic of an in vivo device.
- Lack of IVD Characteristics: There is no mention of the device being used to test samples of human origin in vitro to provide information about a physiological state, health, or disease. The device facilitates the collection of samples, but it doesn't perform the diagnostic testing itself.
Therefore, the BardPort® and SlimPort™ Implanted Ports are considered medical devices for in vivo use, not IVDs.
N/A
# Intended Use / Indications for Use
The BardPort® and SlimPort™ Implanted Ports are indicated for patient therapies requiring repeated access to the vascular system. The port system can be used for infusion of medications, I.V. fluids, parenteral nutrition solutions, blood products and for the withdrawal of blood samples.
# Product codes
LJT
# Device Description
The X-Port isp port relies on the same basic, fundamental scientific technology as the predicate Hickman port. Access to the port is made percutaneously with a non-coring needle that enters the port reservoir via the silicone rubber septum. The access path to the vascular system is provided through a catheter attached to the port. The port system serves as a conduit for fluids into, and out of, the central venous system.
The port body consists of an oval shaped plastic base and top. The silicone septum is compressed between the port base and top. The port body profile incorporates smooth transitions, a tapered nose and is intermediate sized.
There are only two suture holes, which are adjacent to the stem and are filled with silicone plugs.
The catheters, stems and catheter locks used with the X-Port isp port are unchanged, previously qualified legally marketed devices covered by the predicate device and come in multiple French sizes.
# Mentions image processing
Not Found
# Mentions AI, DNN, or ML
Not Found
# Input Imaging Modality
Not Found
# Anatomical Site
vascular system
# Indicated Patient Age Range
Not Found
# Intended User / Care Setting
Not Found
# Description of the training set, sample size, data source, and annotation protocol
Not Found
# Description of the test set, sample size, data source, and annotation protocol
Not Found
# Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation testing was performed according to protocols based on the above-referenced guidance document recommendations and standards, as well as in accordance with in-house protocols.
Port tests performed in conformance with Guidance on 510(k) Submission for Implanted Infusion Ports, dated October 1990 included assessments of:
- Dimensions
- Septum puncture life
- Intermittent port leak
- Continuous port leak
- Septum blowout
- Fluid dynamics clearance
The following guidance recommended tests were not performed for the following reasons:
- All catheter to port connection tests. All catheters and catheter/port connection systems are part of previously qualified legally marketed devices covered by the predicate device and have been incorporated into the X-Port isp port with no change. The only modifications are to the main port body.
- No biocompatibility testing was required. All materials used in the manufacture of the subject device have been previously cleared for similar devices.
In addition, the following verification tests were performed to further demonstrate the safety and efficacy of the subject device for its intended use:
- Flow rate
- Obturation
- Priming volume
- Septum needle insertion force
- Septum needle retention force
- Stem strength
- Suture plug retention
- Top/base assembly strength
Performance data gathered in design verification and validation testing demonstrated that the X-Port isp port is substantially equivalent to the predicate Hickman port and/or met predetermined acceptance criteria, and the risks associated with use of the new device were found acceptable when evaluated by FMEA.
The X-Port isp port met all predetermined acceptance criteria.
# Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
# Predicate Device(s)
[K873213](https://510k.innolitics.com/search/K873213)
# Reference Device(s)
Not Found
# Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5965 Subcutaneous, implanted, intravascular infusion port and catheter.
(a)
Identification. A subcutaneous, implanted, intravascular infusion port and catheter is a device that consists of a subcutaneous, implanted reservoir that connects to a long-term intravascular catheter. The device allows for repeated access to the vascular system for the infusion of fluids and medications and the sampling of blood. The device consists of a portal body with a resealable septum and outlet made of metal, plastic, or combination of these materials and a long-term intravascular catheter is either preattached to the port or attached to the port at the time of device placement. The device is available in various profiles and sizes and can be of a single or multiple lumen design.(b)
Classification. Class II (special controls) Guidance Document: “Guidance on 510(k) Submissions for Implanted Infusion Ports,” FDA October 1990.
0
Section 6
510(k) Summary X-Port isp Implanted Port
510(k) Summary of Safety and Effectiveness Information 21CFR 807.92
6.1 Submitter Information
| Submitter Name: | Bard Access Systems, Inc. (BAS)
[Subsidiary of C. R. Bard, Inc.] |
|----------------------|---------------------------------------------------------------------|
| Address: | 5425 W. Amelia Earhart Drive
Salt Lake City, UT 84116 |
| Telephone Number: | (801) 595-0700, Ext. 5439 |
| Fax Number: | (801) 595-5425 |
| Contact Person: | John Knorpp |
| Date of Preparation: | 6 September 2002 |
6.2 Device Name
| Device Name: | BardPort® Implanted Port |
|---|---|
| Trade Name: | X-Port isp™ |
| Common/Usual Name: | Plastic Subcutaneous Port & Catheter |
| Classification Name: | 80LJT - Port & Catheter, Implanted, Subcutaneous, Intravascular |
| 21 CFR 880.5965 - Subcutaneous, Implanted, Intravascular Infusion | |
| Port and Catheter, Class II |
6.3 Predicate Device Name
| Device Name: | BardPort Implanted Port |
|---|---|
| Trade Name: | Hickman® Plastic Subcutaneous Port |
| Common/Usual Name: | Plastic Subcutaneous Port & Catheter |
| Classification Name: | 80LJT - Port & Catheter, Implanted, Subcutaneous, Intravascular |
| 21 CFR 880.5965 – Subcutaneous, Implanted, Intravascular Infusion | |
| Port and Catheter, Class II | |
| Premarket Notification: | K873213, concurrence date – October 27, 1987. |
6.4 Device Description
Principles of Operation
There are no new operating principles. The X-Port isp port relies on the same basic, fundamental scientific technology as the predicate Hickman port. Access to the port is made percutaneously with a non-coring needle that enters the port reservoir via the silicone rubber septum. The access path to the vascular system is provided through a catheter attached to the port. The port system serves as a conduit for fluids into, and out of, the central venous system.
Port Body
- The port body consists of an oval shaped plastic base and top. ●
- . The silicone septum is compressed between the port base and top.
- . The port body profile incorporates smooth transitions, a tapered nose and is intermediate sized.
1
- There are only two suture holes, which are adjacent to the stem and are filled with silicone . plugs.
Catheters, Stems and Catheter Locks
- The catheters, stems and catheter locks used with the X-Port isp port are unchanged, previously ● qualified legally marketed devices covered by the predicate device and come in multiple French sizes.
6.5 Intended Use
The BardPort X-Port isp Implanted Port is a totally implantable vascular access device designed to provide long term repeated access to the vascular system.
This is the identical intended use for the predicate Hickman port.
6.6 Summary of Technological Characteristics in Relation to the Predicate Device
- 6.6.1 Does the new device have the same indication statement?
Yes.
Does the new device have the same technological characteristics, e.g. design, material, 6.6.2 etc.?
Not in all regards. The X-Port isp port design has some minor differences from the predicate Hickman port, however the basic fundamental scientific technology of the port has not changed. The differences include the following: a larger septum, a lower profile intermediate size port body, two silicone filled suture holes located adjacent to the stem and a tapered nose.
6.6.3 Could the new characteristics affect safety or effectiveness?
Yes. The above features could affect safety or effectiveness of the device.
6.6.4 Do the new characteristics raise new types of safety and effectiveness questions?
No. There are no new issues of safety and effectiveness.
6.6.5 Do accepted scientific methods exist for assessing effects of the new characteristics?
Yes. The FDA's Guidance on 510(k) Submissions for Implanted Infusion Ports, dated October 1990 was used to evaluate the device's performance.
Design validation was performed to meet the recommendations of the FDA guidance document, Design Control Guidance for Medical Device Manufacturers, dated March 11, 1997.
Biocompatibility requirements of ISO-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing, and the FDA-Modified ISO 10993 Test Profile for a long term implanted device that exhibits tissue contact, indirect blood contact and direct blood contact, were met. No materials are used in the manufacture of the subject device that have not already been cleared for similar applications by Bard Access Systems.
6.6.6 Are performance data available to assess effects of new characteristics?
2
Yes. Verification and validation testing was performed according to protocols based on the above-referenced guidance document recommendations and standards, as well as in accordance with in-house protocols.
6.6.7 Do performance data demonstrate equivalence?
Yes. Performance data gathered in design verification and validation testing demonstrated that the X-Port isp port is substantially equivalent to the predicate Hickman port and/or met predetermined acceptance criteria, and the risks associated with use of the new device were found acceptable when evaluated by FMEA.
6.7 Nonclinical Performance Testing
Port tests performed in conformance with Guidance on 510(k) Submission for Implanted Infusion Ports, dated October 1990 included assessments of:
- . Dimensions
- . Septum puncture life
- Intermittent port leak .
- Continuous port leak .
- . Septum blowout
- . Fluid dynamics clearance
The following guidance recommended tests were not performed for the following reasons:
- All catheter to port connection tests. All catheters and catheter/port connection systems are part . of previously qualified legally marketed devices covered by the predicate device and have been incorporated into the X-Port isp port with no change. The only modifications are to the main port body.
- . No biocompatibility testing was required. All materials used in the manufacture of the subject device have been previously cleared for similar devices.
In addition, the following verification tests were performed to further demonstrate the safety and efficacy of the subject device for its intended use:
- . Flow rate
- Obturation .
- . Priming volume
- . Septum needle insertion force
- . Septum needle retention force
- . Stem strength
- . Suture plug retention
- Top/base assembly strength .
6.8 Conclusion
The X-Port isp port met all predetermined acceptance criteria.
Based on FDA's decision tree, the X-Port isp port is substantially equivalent to the predicate device Hickman Port, K873213, cleared October 27, 1987.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling three stylized human figures or birds in flight, arranged in a stacked formation.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. John C. Knorpp Senior Regulatory Affairs Manager C. R. Bard, Incorporated Bard Access Systems Division 5425W. Amelia Earhart Drive Salt Lake City, Utah 84116
Re: K022983
Trade/Device Name: The BardPort® and SlimPort™ Implanted Ports Regulation Number: 880.5965 Regulation Name: Subcutaneous. Implanted, Intravascular Infusion Port and Catheter Regulatory Class: II Product Code: LJT Dated: September 6, 2002 Received: September 9, 2002
Dear Mr. Knorpp:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting vour device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.qov/cdrh/dsma/dsmamain.html
Sincerely yours,
Timothy A. Ulatowski
Timothy A. Ulatowski Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Section 1.2
INDICATION(S) FOR USE STATEMENT*
The BardPort® and SlimPort™ Implanted Ports are indicated for patient therapies requiring repeated access to the vascular system. The port system can be used for infusion of medications, I.V. fluids, parenteral nutrition solutions, blood products and for the withdrawal of blood samples.
Signature of 510(k) Submitter:
Printed Name of Submitter:
John C. Thoyt
John C. Knorpp Senior Regulatory Affairs Specialist
Date:
9-6-02
*Suggested language and format to meet the requirements of sections 513(i) of the Federal Food, Drug, and Cosmetic Act, as amended, and sections 807.92(a)(5) and 801.4 of the Code of Federal Regulations, Title 21.
Concurrence of Office of Device Evaluation
510(k) Number
OR
2
Division Sign-Off Office of Device Evaluation
Prescription Use
Over-The-Counter Use
Patux Cicardi
vision Sian-Off Division of Anesthesiology, General Hospital. Infection Control, Dental Devices
510(k) Number: K022983